股。 分公司完成回购注销手续。 公司于 2023 年 11 月 13 日召开第九届董事会第二十二次会议、第九届监事会 第十八次会议、2023 年 11 月 29 日召开 2023 年第四次临时股东大会审议通过了 《关于拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除限售的限 制性股票的议案》；于 2024 年 7 月 25 日召开第九届董事会第二十八次会议、第 九届监事会第二十二次会议、2024 年 9 月 12 日召开 2024 年第二次临时股东大会 审议通过了《关于拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除 限售的限制性股票的议案》，现将有关事项说明如下： 一、公司 2022 年限制性股票激励计划已履行的相关审批程序 于公司〈2022 年限制性股票激励计划（草案）〉及其摘要的议案》 证券代码：000597 证券简称：东北制药 公告编号：2025-048 东北制药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 股票激励计划所涉及的 26 名不符合条件的激励对象持有的部分或全部已获授但 尚未解除限 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-048 东北制药集团股份有限公司 1.东北制药集团股份有限公司（以下简称"公司"）已完成对 2022 年限制性 股票激励计划所涉及的 26 名不符合条件的激励对象持有的部分或全部已获授但 尚未解除限售的 2,015,000 股限制性股票进行回购注销，占回购注销前公司总股 本的 0.1410%。 2.回购注销完成后，公司总股本将由 1,429,103,265 股减少至 1,427,088,265 股。 3.截至本公告日，上述限制性股票已在中国证券登记结算有限责任公司深圳 分公司完成回购注销手续。 公司于 2023 年 11 月 13 日召开第九届董事会第二十二次会议、第九届监事会 第十八次会议、2023 年 11 月 29 日召开 2023 年第四次临时股东大会审议通过了 《关于拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除限售的限 制性股票的议案》；于 2024 年 7 月 25 日召开第九届董事会第二十八次会议、第 九届监事会第二十二次会议、2024 年 9 月 12 日召开 2024 年第二次临时股东大会 审议通过了《关于拟回 ...

Core Insights - Northeast Pharmaceutical has officially obtained the CEP certificate for its core raw material product, fosfomycin trometamol, from the European Directorate for the Quality of Medicines (EDQM), marking a significant milestone as the first domestic pharmaceutical company to achieve this certification [1][2] - The CEP certificate serves as a "golden key" for entering the European and American markets, indicating that the product meets stringent quality standards that exceed typical international registration requirements [2] - The certification enhances Northeast Pharmaceutical's international brand value and strengthens China's position in the global antibiotic sector [2][3] Market Potential - Fosfomycin trometamol is recognized for its low resistance characteristics and is suitable for treating various infections, making it highly relevant in the context of the global antibiotic resistance crisis [3] - The demand for high-quality antibiotic raw materials in the European market is on the rise, and the CEP certification is expected to boost the market penetration of Northeast Pharmaceutical's products in Europe [3] Competitive Position - Northeast Pharmaceutical has established a robust international registration matrix, with approximately 20 raw material products having passed high-end registrations in various countries, including the EU, Japan, and Russia [4] - The company is a major supplier of vitamin C and holds significant positions in the global supply of fosfomycin and chloramphenicol, maintaining a competitive edge in the international market [4] - The company aims to leverage its CEP registration to enhance its global market share and transition from "product export" to "brand export," thereby gaining greater international respect for Chinese pharmaceuticals [5]

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]

Core Viewpoint - The legal opinion from Beijing Deheng Law Firm confirms that Jiangxi Fangda Steel Group Co., Ltd., an action-in-concert party of the controlling shareholder, plans to increase its stake in Northeast Pharmaceutical Group Co., Ltd. This move is based on confidence in the company's future development and aims to enhance its market value [2][4]. Group 1: Shareholder Information - The increasing party, Fangda Steel, was established in May 1959 with a registered capital of 1,035.339 million RMB and operates in various sectors including steel production and trade [4][5]. - Fangda Steel has confirmed that it does not fall under any prohibitive conditions for acquiring shares as per the relevant regulations [5][6]. Group 2: Details of the Increase - The planned increase in shares is between 75 million RMB and 150 million RMB [6]. - The increase will be executed through the Shenzhen Stock Exchange within six months starting from December 11, 2024, and will be based on market conditions [6][7]. - The funding for this increase will come from Fangda Steel's own funds and special loans [6][7]. Group 3: Compliance and Disclosure - The increase is structured to comply with the regulations, including a commitment not to sell shares for six months post-increase [7][9]. - The controlling shareholders and their concerted actions will not change as a result of this increase, thus not affecting the company's listing status [8][9]. - The company has fulfilled its current disclosure obligations regarding this increase [9].

证券代码：000597 证券简称：东北制药 公告编号：2025-047 东北制药集团股份有限公司关于控股股东一致行动人 增持计划实施完成的公告 公司控股股东一致行动人江西方大钢铁集团有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 方大集团实业有限公司（简称"方大集团"）一致行动人江西方大钢铁集团有限 公司（以下简称"方大钢铁/增持主体"）计划自 2024 年 12 月 11 日起 6 个月内 增持公司股份，计划增持金额不少于人民币 7,500 万元,不超过人民币 15,000 万 元。 圳证券交易所以集中竞价交易方式合计增持公司股份 14,629,900 股，占公司总 股本比例的 1.0237%，合计增持金额为 7,500.4222 万元（不含交易费用），本次 增持计划已实施完成。 （二）增持计划披露前，增持主体已持有公司股份数量及比例：公司控股股 东为方大集团，直接持有公司 329,068,713 股股份，占公司总股本的 23.03%，方 大钢铁直接持有公司 443,231,442 股 ...

北京德恒律师事务所 关于东北制药集团股份有限公司 控股股东一致行动人 增持公司股份相关事项的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于东北制药集团股份有限公司控股股东一致行动人增持公司股份相关事项的 法律意见 北京德恒律师事务所 北京德恒律师事务所 关于东北制药集团股份有限公司控股股东一致行动人增持公司股份相关事项的 法律意见 告所引述。 3．本法律意见仅依据截至本法律意见出具之日公司提供给本所的相关材料 （包括但不限于书面材料、副本材料、复印材料、口头或书面说明、承诺函或证 明等）发表意见。公司已向本所及本所律师保证了其提供的相关资料的真实性、 准确性和完整性，不存在任何隐瞒、遗漏或者虚假记载，不存在误导之处；文件 材料为扫描件、副本或复印件的，相关信息均与正本或原件一致。 4．本法律意见仅供就本次增持之目的使用，不得用作其他目的。本所同意 将本法律意见随其他材料一并披露。 关于东北制药集团股份有限公司控股股东一致行动人 增持公司股份相关事项的 法律意见 致：东北制药集团股份 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-047 东北制药集团股份有限公司关于控股股东一致行动人 （一）增持主体名称：江西方大钢铁集团有限公司 （二）增持计划披露前，增持主体已持有公司股份数量及比例：公司控股股 东为方大集团，直接持有公司 329,068,713 股股份，占公司总股本的 23.03%，方 大钢铁直接持有公司 443,231,442 股股份，占公司总股本的 31.01%，实际控制人 方威直接持有公司 12,189,130 股股份，占公司总股本的 0.85%。方威间接持有方 大集团 99.20%股份，方大集团 100%持有方大钢铁股份，方大钢铁同方威、方大集 团构成一致行动人，上述一致行动人合计持有的股份数量占公司总股本的 54.89%。 （三）增持主体在 2024 年 12 月 11 日前 12 个月内未增持公司股份，亦未披 露增持计划。 1 增持计划实施完成的公告 公司控股股东一致行动人江西方大钢铁集团有限公司保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： ...

Group 1 - The fourth China (Nanchang) International Health Industry Conference and Expo was inaugurated, showcasing the achievements of Liaoning Fangda Group in the health sector [1] - Liaoning Fangda Group is a diversified large enterprise group with multiple listed companies across various sectors, including pharmaceuticals, and is focusing on enhancing its pharmaceutical business [1][2] - Northeast Pharmaceutical, a subsidiary of Liaoning Fangda Group, is a major supplier of vitamin C and has made significant progress in international certifications, including receiving the CEP certificate for its raw material phosphomycin [2] Group 2 - Liaoning Fangda Group is investing nearly 10 billion yuan to establish Liaoning Fangda General Hospital, which will feature advanced medical technologies and a capacity of 5,000 beds [3] - The hospital aims to set a new benchmark for private hospitals in China by integrating public welfare attributes with private mechanisms and has formed strategic partnerships with top medical institutions [3] - The health industry is identified as a future growth sector, with Liaoning Fangda Group planning to develop a comprehensive health ecosystem through the Fangda Health City project [4]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]